Clinical Trials Directory

Trials / Sponsors / Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Industry · 6 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnCD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Metastatic Melanoma
Phase 1 / Phase 22021-06-15
TerminatedEfprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myelo
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia
Phase 32021-01-05
TerminatedEfprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in
HIV Infections, Dyslipidemias
Phase 22020-08-31
CompletedEfprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Coronavirus Disease 2019 (COVID-19)
Phase 32020-04-24
CompletedPhase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVH
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Phase 22016-09-19
CompletedSafety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (M
Healthy Volunteers
Phase 12014-06-02